Display options
Cite
Liu T, Fang Z, Wang G, et al. Anti-tumor activity of the TRPM8 inhibitor BCTC in prostate cancer DU145 cells. Oncol Lett. 2015;11(1):182-188doi: 10.3892/ol.2015.3854.
Liu, T., Fang, Z., Wang, G., Shi, M., Wang, X., Jiang, K., Yang, Z., Cao, R., Tao, H., Wang, X., & Zhou, J. (2016). Anti-tumor activity of the TRPM8 inhibitor BCTC in prostate cancer DU145 cells. Oncology letters, 11(1), 182-188. https://doi.org/10.3892/ol.2015.3854
Liu, Tao, et al. "Anti-tumor activity of the TRPM8 inhibitor BCTC in prostate cancer DU145 cells." Oncology letters vol. 11,1 (2016): 182-188. doi: https://doi.org/10.3892/ol.2015.3854
Liu T, Fang Z, Wang G, Shi M, Wang X, Jiang K, Yang Z, Cao R, Tao H, Wang X, Zhou J. Anti-tumor activity of the TRPM8 inhibitor BCTC in prostate cancer DU145 cells. Oncol Lett. 2016 Jan;11(1):182-188. doi: 10.3892/ol.2015.3854. Epub 2015 Nov 02. PMID: 26870186; PMCID: PMC4727066.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2016 Jan;11(1):182-188. doi: 10.3892/ol.2015.3854. Epub 2015 Nov 02.

Anti-tumor activity of the TRPM8 inhibitor BCTC in prostate cancer DU145 cells.

Oncology letters

Tao Liu, Zhihai Fang, Gang Wang, Mingjun Shi, Xiao Wang, Kun Jiang, Zhonghua Yang, Rui Cao, Huangheng Tao, Xinghuan Wang, Jiajie Zhou

Affiliations

  1. Department of Urology, Jingzhou Central Hospital, Jingzhou, Hubei 434020, P.R. China.
  2. Department of Urology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, P.R. China.
  3. Key Laboratory for Oral Biomedicine of Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei 430079, P.R. China.

PMID: 26870186 PMCID: PMC4727066 DOI: 10.3892/ol.2015.3854

Abstract

The present study investigated the anti-tumor activity of N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide (BCTC), a potent and specific inhibitor of transient receptor potential cation channel subfamily M member 8 (TRPM8) in prostate cancer (PCa) DU145 cells. TRPM8 expression in DU145 and normal prostate PNT1A cells was detected by reverse transcription polymerase chain reaction and western blot analysis. The effect of BCTC on DU145 cells was analyzed by flow cytometry analysis, and MTT, scratch motility and Transwell invasion assays. The molecular mechanism through which BCTC acts was investigated by western blot analysis. TRPM8 expression was increased in DU145 cells compared with PNT1A cells at the mRNA and protein levels. The present study provided evidence that inhibition of TRPM8 by BCTC reduced the viability of DU145 cells, but not PNT1A cells. In addition, BCTC inhibited cell cycle progression, migration and invasion in DU145 cells. Cell cycle-associated proteins, including phosphorylated protein kinase B, cyclin D1, cyclin dependent kinase (CDK) 2 and CDK6 were downregulated by BCTC, while phosphorylated glycogen synthase kinase 3β was upregulated. However, investigations in the present study revealed that BCTC failed to trigger apoptosis in DU145 cells. In addition, in BCTC-treated DU145 cells, phosphorylated extracellular signal-regulated kinase 1/2 was downregulated substantially while phosphorylated p38 (p-p38) and phosphorylated c-Jun N-terminal kinases (p-JNK) were upregulated. The anti-proliferative activity of BCTC on DU145 cells was attenuated by p38 and JNK-specific inhibitors, suggesting that MAPK pathways are involved. Overall, the TRPM8 specific antagonist BCTC demonstrated excellent anti-tumor activity in PCa DU145 cells, and therefore has the potential to become a targeted therapeutic strategy against PCa.

Keywords: BCTC; TRPM8; inhibitor; prostate cancer; targeted therapy

References

  1. Prostate Int. 2013;1(2):47-58 - PubMed
  2. J Physiol. 2007 May 15;581(Pt 1):155-74 - PubMed
  3. Nat Med. 2004 Jan;10(1):33-9 - PubMed
  4. Cell Biochem Biophys. 2005;43(3):451-61 - PubMed
  5. Cancer Res. 2001 May 1;61(9):3760-9 - PubMed
  6. Cancer Res. 2004 Nov 15;64(22):8365-73 - PubMed
  7. Cancer Res. 2003 Jul 15;63(14):4196-203 - PubMed
  8. Asian J Androl. 2009 Mar;11(2):150-1 - PubMed
  9. Mol Cancer. 2007 Apr 02;6:24 - PubMed
  10. Lancet. 2008 May 17;371(9625):1710-21 - PubMed
  11. Nat Rev Mol Cell Biol. 2007 Mar;8(3):221-33 - PubMed
  12. Oncogene. 2001 Mar 8;20(10):1152-63 - PubMed
  13. Cancer Biol Ther. 2012 Jun;13(8):592-9 - PubMed
  14. Pathol Oncol Res. 2012 Oct;18(4):903-10 - PubMed
  15. Biochim Biophys Acta. 2009 Jun;1793(6):1105-9 - PubMed
  16. Asian J Androl. 2009 Mar;11(2):157-65 - PubMed
  17. Nat Clin Pract Oncol. 2007 Apr;4(4):236-44 - PubMed
  18. Lancet Oncol. 2009 Oct;10(10):981-91 - PubMed
  19. Cancer Biol Med. 2013 Dec;10(4):187-91 - PubMed
  20. Exp Eye Res. 2013 Nov;116:337-49 - PubMed
  21. J Natl Cancer Inst. 1999 Nov 3;91(21):1869-76 - PubMed
  22. Nat Rev Urol. 2010 Jan;7(1):31-8 - PubMed
  23. Pflugers Arch. 2011 Jan;461(1):99-114 - PubMed
  24. Biochim Biophys Acta. 2007 Aug;1772(8):937-46 - PubMed
  25. Biol Cell. 2004 Feb;96(1):47-54 - PubMed
  26. J Neurosci. 2006 Nov 29;26(48):12512-25 - PubMed
  27. Clin Cancer Res. 2008 Feb 1;14(3):627-32 - PubMed
  28. Clin Cancer Res. 1998 Jun;4(6):1393-403 - PubMed
  29. PLoS One. 2012;7(12):e51825 - PubMed
  30. Can J Oncol. 1996 Jun;6(1):443-57 - PubMed
  31. Int J Oncol. 2012 May;40(5):1431-40 - PubMed

Publication Types